Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGPL1 | O95470 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 7/20 | 0.38 |
| ▸ | ACACA | Q13085 | 3/20 | 0.38 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL908176 | 1.00 | SGPL1 (0.40) | SGPL1ACACBACACARAF1BRAF | |
| SCHEMBL907829 | 0.93 | P2RY12 (0.43) | SGPL1P2RY12 | |
| SCHEMBL907828 | 0.93 | P2RY12 (0.43) | SGPL1P2RY12 | |
| SCHEMBL908007 | 0.93 | P2RY12 (0.38) | RAF1BRAFP2RY12PIK3CA | |
| SCHEMBL908412 | 0.91 | SYK (0.37) | ACACBACACARAF1BRAFMAP3K12 | |
| SCHEMBL908415 | 0.91 | SYK (0.37) | ACACBACACARAF1BRAFMAP3K12 | |
| SCHEMBL908082 | 0.90 | SGPL1 (0.43) | SGPL1ACACBACACAP2RY12MAP3K12 | |
| SCHEMBL908080 | 0.90 | SGPL1 (0.43) | SGPL1ACACBACACAP2RY12MAP3K12 | |
| SCHEMBL908338 | 0.88 | SGPL1 (0.49) | SGPL1ACACBACACAP2RY12SMO | |
| SCHEMBL908339 | 0.88 | SGPL1 (0.49) | SGPL1ACACBACACAP2RY12SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786800-B1 | 1,4-Diarylpiperazine derivatives as capsaicin receptor modulators for treating pain | NEUROGEN CORP (US) | 2017-01-04 | — | — | EP | claimed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | claimed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | claimed |
| EP-1786800-A4 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORP (US) | 2009-05-06 | — | — | EP | claimed |
| EP-1786800-A2 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-05-23 | — | — | EP | claimed |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2006-06-08 | — | — | US | claimed |
| WO-2006026135-A2 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-03-09 | — | — | WO | claimed |
| EP-1786800-B1 | 1,4-Diarylpiperazine derivatives as capsaicin receptor modulators for treating pain | NEUROGEN CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-1786800-B1 | 1,4-Diarylpiperazine derivatives as capsaicin receptor modulators for treating pain | NEUROGEN CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-8334382-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334382-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334382-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | GPR88, PIGO, PRLHR | SGPL1 3448/4885ACACB 3035/4885ACACA 3323/4885 |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | GPR88, PRLHR, GPR68 | SGPL1 3473/4885ACACB 3022/4885ACACA 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.